Paying users zone. Data is covered by hidden.

  • Get 1 month access to Bristol-Myers Squibb Co. for $17.99, or

  • get full access to entire website for at least 3 months from $49.99.


We accept:

Visa Mastercard American Express Maestro Discover JCB PayPal Apple Pay Google Pay
Verified by Visa MasterCard SecureCode American Express SafeKey

Microsoft Excel LibreOffice Calc

Bristol-Myers Squibb Co. (BMY)


Common-Size Statement of Financial Position, Liabilities and Stockholders’ Equity

Difficulty: Beginner

Bristol-Myers Squibb Co., Common-Size Consolidated Statement of Financial Position, Liabilities and Stockholders’ Equity

Microsoft Excel LibreOffice Calc
Dec 31, 2018 Dec 31, 2017 Dec 31, 2016 Dec 31, 2015 Dec 31, 2014
Short-term debt obligations hidden hidden hidden hidden hidden
Accounts payable hidden hidden hidden hidden hidden
Rebates and returns hidden hidden hidden hidden hidden
Employee compensation and benefits hidden hidden hidden hidden hidden
Research and development hidden hidden hidden hidden hidden
Dividends hidden hidden hidden hidden hidden
Royalties hidden hidden hidden hidden hidden
Branded Prescription Drug Fee hidden hidden hidden hidden hidden
Liabilities related to assets held-for-sale hidden hidden hidden hidden hidden
Litigation and other settlements hidden hidden hidden hidden hidden
Restructuring hidden hidden hidden hidden hidden
Pension and postretirement benefits hidden hidden hidden hidden hidden
Other hidden hidden hidden hidden hidden
Accrued liabilities hidden hidden hidden hidden hidden
Deferred income hidden hidden hidden hidden hidden
Income taxes payable hidden hidden hidden hidden hidden
Current liabilities hidden hidden hidden hidden hidden
Deferred income hidden hidden hidden hidden hidden
Income taxes payable hidden hidden hidden hidden hidden
Pension and other liabilities hidden hidden hidden hidden hidden
Long-term debt, excluding current portion hidden hidden hidden hidden hidden
Non-current liabilities hidden hidden hidden hidden hidden
Total liabilities hidden hidden hidden hidden hidden
Preferred stock, $2 convertible series, par value $1 per share hidden hidden hidden hidden hidden
Common stock, par value of $0.10 per share hidden hidden hidden hidden hidden
Capital in excess of par value of stock hidden hidden hidden hidden hidden
Accumulated other comprehensive loss hidden hidden hidden hidden hidden
Retained earnings hidden hidden hidden hidden hidden
Cost of treasury stock hidden hidden hidden hidden hidden
Total Bristol-Myers Squibb Company shareholders’ equity hidden hidden hidden hidden hidden
Noncontrolling interest hidden hidden hidden hidden hidden
Total equity hidden hidden hidden hidden hidden
Total liabilities and equity hidden hidden hidden hidden hidden

Based on: 10-K (filing date: 2019-02-25), 10-K (filing date: 2018-02-13), 10-K (filing date: 2017-02-21), 10-K (filing date: 2016-02-12), 10-K (filing date: 2015-02-13).

Item Description The company
Current liabilities Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer. Bristol-Myers Squibb Co.’s current liabilities as a percentage of total liabilities and equity increased from 2016 to 2017 and from 2017 to 2018.
Non-current liabilities Amount of obligation due after one year or beyond the normal operating cycle, if longer. Bristol-Myers Squibb Co.’s non-current liabilities as a percentage of total liabilities and equity increased from 2016 to 2017 but then slightly declined from 2017 to 2018 not reaching 2016 level.
Total liabilities Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future. Bristol-Myers Squibb Co.’s total liabilities as a percentage of total liabilities and equity increased from 2016 to 2017 but then slightly declined from 2017 to 2018.
Total Bristol-Myers Squibb Company shareholders’ equity Total of all stockholders’ equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity’s stockholders’ equity attributable to the parent excludes the amount of stockholders’ equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity. Bristol-Myers Squibb Co.’s total Bristol-Myers Squibb Company shareholders’ equity as a percentage of total liabilities and equity declined from 2016 to 2017 but then slightly increased from 2017 to 2018.